An interventional study of Single dose tamsulosin 0.4mg and Double dose tamsulosin 0.4mg in Prostatic Neoplasms, Prostate Disease and Prostate Obstruction, sponsored by Menoufia University. Completed at 1 site in Egypt. Open to male participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-04-28.
Sponsored by Menoufia University · Not applicable, Interventional, and Treatment
Single dose versus double dose tamsulosin in Management of Moderate and severe lower urinary tract symptoms due to benign prostatic hyperplasia
6,484 studies on the registry are indexed under Prostatic Neoplasms; 1,415 are open to participants now.
This study's enrollment of 60 is close to the median of 58 across 4,908 interventional studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →Menoufia University is the lead sponsor of 197 studies on the registry; 53 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Single dose tamsulosin 0.4mg
Drug: Single dose tamsulosin 0.4mg
Double dose tamsulosin 0.4mg
Drug: Double dose tamsulosin 0.4mg
Single dose tamsulosin 0.4mg
Double dose tamsulosin 0.4mg
Change in the lower urinary tract symptoms
Assessed by the improvement in the internal prostatic symptoms score (IPSS)
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.